EGFR-targeted therapy drugs like Cetuximab and Trastuzumab, which are already in the use for treatment of NSCLC and metastatic CRC, lead to a better prognosis and have recently been suggested as potential treatments for ovarian cancer because of the overexpression of EGFR in ovarian cancer (26). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.